Neurology

Is the cost of specialty drugs worth the price in small patient populations?

Four genes found linked to epigenetic mechanisms that contribute to multiple sclerosis.

Resistance and endurance exercises may improve muscle growth and repair in multiple sclerosis patients.

Mice treated with rapamycin showed improved locomotor function and reduced sensitivity.

Evidence builds supporting the use of fecal transplants to treat infections in the gut microbiome.

Levels of good and bad gut bacteria influences autoimmune disease.

Obstructive sleep apnea in MS patients can lead to deeper problems.

Transplanting human stem cells into the spinal cord of patients with amyotrophic lateral sclerosis (ALS) shows promise.

The amount of cerebral microbleeds can influence the severity of physical and cognitive outcomes in MS patients.

Dimethylfumarate could provide a new treatment option for several neurodegenerative diseases.

Ocrevus treats relapsing and primary progressive multiple sclerosis.

While cancer spending contributes largely to medical spending, it only accounted for 6.3% of growth from 2000 to 2012.

Ocrevus is an investigational, humanized monoclonal antibody that selectively targets CD20-positive B cells in multiple sclerosis.

Findings will allow for improved screenings of drugs that treat MS.

Intensive stem cell transplant cleared all signs of brain inflammation in multiple sclerosis patients.

Gut bacteria found to influence the activity of cells in the brain that control inflammation and neurodegeneration.

Study finds social media content can be analyzed for use in MS outcomes research.

Patients with mutations in the gene NR1H3 have a 70% chance of developing a progressive form of MS.

Daclizumab (Zinbryta) treats adults with relapsing forms of multiple sclerosis.

Zinbryta is a long-acting injection that is self-administered by the patient every month.

The FDA has approved daclizumab (Zinbryta) as a treatment for adults with relapsing forms of multiple sclerosis.

Conditions such as multiple sclerosis, epilepsy and Parkinson’s disease may cause sexual dysfunction.

Fingolimod (Gilenya) has shown inconsistent improvements with disability in multiple sclerosis.

Various benefits associated with fingolimod (Gilenya) observed for relapsing-remitted multiple sclerosis.